{
    "nctId": "NCT01891669",
    "briefTitle": "A Study Of PF-06263507 In Patients With Advanced Solid Tumors",
    "officialTitle": "A PHASE 1, DOSE ESCALATION STUDY OF PF-06263507 IN PATIENTS WITH ADVANCED SOLID TUMORS",
    "overallStatus": "TERMINATED",
    "conditions": "Neoplasms, Carcinoma, Non Small Cell Lung, Breast Neoplasms, Ovarian Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 26,
    "primaryOutcomeMeasure": "Number of Participants With Dose-limiting Toxicities (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for which no standard therapy is available.\n* Performance Status of 0 or 1.\n* Adequate bone marrow, kidney, liver, and heart function.\n\nExclusion Criteria:\n\n* Brain metastases requiring steroids.\n* Major surgery or anti-cancer therapy within 4 weeks of study treatment start.\n* Active bacterial, fungal or viral infection.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}